Typhoid Fever Vaccines Market Size, Share, Growth, and Industry Analysis, By Type (Live Attenuated Vaccine, Conjugate Vaccine, Capsular Polysaccharide Vaccines, Others), By Application (Government Institution, Private Sector), Regional Insights and Forecast to 2034

Typhoid Fever Vaccines Market Overview

The Typhoid Fever Vaccines Market size was valued at USD 233.52 million in 2025 and is expected to reach USD 386.79 million by 2034, growing at a CAGR of 5.2% from 2025 to 2034.

The Typhoid Fever Vaccines Market is closely linked to the global burden of typhoid fever, which causes an estimated 11 million to 20 million cases annually, resulting in approximately 128,000 to 161,000 deaths worldwide. More than 2 billion people live in regions with inadequate sanitation, increasing the at-risk population. Over 45 countries have introduced typhoid conjugate vaccines (TCVs) into routine immunization programs targeting children aged 6 months to 15 years. More than 200 million TCV doses have been supplied globally between 2018 and 2024. Government procurement accounts for nearly 75% of total vaccine volumes, strengthening the Typhoid Fever Vaccines Market Size and Typhoid Fever Vaccines Market Growth across endemic regions.

In the United States, typhoid fever results in approximately 300 to 400 confirmed cases annually, with over 80% linked to international travel. Around 3 million U.S. residents travel each year to South Asia, Africa, and Latin America, which are high-incidence regions. The Advisory Committee on Immunization Practices recommends vaccination for travelers, laboratory workers, and close contacts of carriers. More than 250,000 typhoid vaccine doses are distributed annually in the U.S. through travel clinics and pharmacies. Adult travelers account for over 95% of U.S. typhoid vaccinations, reinforcing the Typhoid Fever Vaccines Market Outlook in non-endemic developed markets.

• 

  Download Free sample to learn more about this report.

Key Findings

• Key Market Driver:75% government procurement reliance; 60% pediatric immunization targeting; 85% endemic population exposure; 70% routine schedule integration; 65% donor-supported programs.
• Major Market Restraint:35% cold-chain gaps; 25% rural access limitation; 20% multi-dose compliance drop; 30% funding dependency; 15% awareness deficit.
• Emerging Trends:55% shift toward conjugate vaccines; 40% single-dose preference; 35% co-administration strategy; 28% adult traveler expansion; 22% digital tracking adoption.
• Regional Leadership:Asia-Pacific 68%; Africa 18%; North America 6%; Europe 5%; Latin America 3%.
• Competitive Landscape:Top 3 manufacturers 70%; public-sector share 75%; export-driven supply 60%; tender-based procurement 72%; WHO-prequalified vaccines 65%.
• Market Segmentation:Conjugate vaccines 58%; Live attenuated 20%; Capsular polysaccharide 18%; Others 4%; Government institutions 78%; Private sector 22%.
• Recent Development:30% capacity expansion; 25% new country introductions; 18% dose optimization trials; 20% campaign scale-up; 15% cold-chain upgrades.

Typhoid Fever Vaccines Market Latest Trends

The Typhoid Fever Vaccines Market Trends indicate a strong transition toward typhoid conjugate vaccines, which account for 58% of global administered doses due to improved immunogenicity in children under 2 years. Over 120 million TCV doses were delivered between 2022 and 2024 in Gavi-supported countries. Approximately 45 countries have integrated TCVs into national immunization schedules, targeting cohorts of 5 million to 20 million children per campaign. Vaccine coverage in high-burden districts exceeds 80% during mass campaigns.

Single-dose regimens now represent 60% of total administered volumes, compared to 40% multi-dose regimens in 2015. Digital immunization registries have been implemented in 35% of participating countries, improving coverage tracking accuracy by 20%. Cold-chain expansion projects increased storage capacity by 25% in South Asia and sub-Saharan Africa between 2021 and 2024. WHO-prequalified vaccines account for 65% of international procurement volumes, reinforcing Typhoid Fever Vaccines Market Insights and Typhoid Fever Vaccines Market Forecast for sustained volume-based expansion.

Typhoid Fever Vaccines Market Dynamics

DRIVER

Expansion of typhoid conjugate vaccine introduction in endemic countries.

Typhoid conjugate vaccines have been introduced in over 45 countries since 2018, targeting more than 150 million children aged 6 months to 15 years. Clinical trials demonstrate over 80% protective efficacy in children under 2 years. Mass immunization campaigns in South Asia vaccinated over 30 million children within 12 months. Routine immunization integration in 25 high-burden countries ensures annual birth cohort coverage exceeding 20 million infants. Public-sector procurement accounts for nearly 75% of doses distributed globally. These structured immunization strategies significantly reduce incidence rates by up to 50% in vaccinated districts, supporting Typhoid Fever Vaccines Market Growth and Typhoid Fever Vaccines Industry Analysis.

RESTRAINT

Infrastructure and funding limitations in low-income regions.

Approximately 35% of rural health facilities in sub-Saharan Africa lack continuous cold-chain systems. Vaccine wastage rates during outreach programs range between 10% and 15%. Around 30% of immunization budgets in low-income countries depend on external donor funding. Multi-dose regimens can result in a 20% drop-off between first and second doses. Surveillance systems cover only 60% of high-risk districts, leading to underreporting. Awareness gaps affect nearly 25% of target populations. These factors limit consistent uptake and create variability in Typhoid Fever Vaccines Market Size across underserved regions.

OPPORTUNITY

Rising antimicrobial resistance and urbanization.

Multidrug-resistant Salmonella Typhi strains account for over 30% of reported cases in South Asia. Extensively drug-resistant strains have been identified in at least 5 countries since 2016. Urban population growth of 2% annually in endemic regions increases transmission risk among dense populations exceeding 500 persons per square kilometer. Preventive vaccination can reduce antibiotic use by 40% in vaccinated communities. Integration with water, sanitation, and hygiene programs in over 20 countries offers bundled public health initiatives. These factors expand Typhoid Fever Vaccines Market Opportunities for long-term immunization strategies.

CHALLENGE

Epidemiological variability and vaccine hesitancy.

Typhoid incidence varies from fewer than 10 cases per 100,000 in some regions to over 300 per 100,000 in high-burden urban districts. Seasonal outbreaks during monsoon periods increase case numbers by 15% to 25%. Vaccine hesitancy affects approximately 12% of eligible caregivers in certain districts. Logistic delays impact 18% of scheduled campaigns. Regulatory approval timelines in emerging markets range between 12 and 24 months. These uncertainties influence Typhoid Fever Vaccines Market Outlook and complicate volume forecasting in the Typhoid Fever Vaccines Market Research Report.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

The Typhoid Fever Vaccines Market Segmentation is categorized by vaccine type and application. Conjugate vaccines hold 58% share due to suitability for children under 2 years. Live attenuated vaccines account for 20%, primarily for travelers and private-sector immunization. Capsular polysaccharide vaccines represent 18%, used in individuals over 2 years. Other formulations contribute 4%. Government institutions account for 78% of procurement volume, while the private sector represents 22%. The Typhoid Fever Vaccines Market Share is highly influenced by national immunization schedules and mass vaccination campaigns covering over 150 million children globally.

By Type

Live Attenuated Vaccine:Live attenuated oral vaccines account for 20% of global volumes. A 3-dose regimen administered over 7 days provides protection for up to 5 years. Approximately 250,000 doses are distributed annually in North America and Europe for travel vaccination. Protective efficacy ranges between 50% and 80%. Cold-chain requirements remain at 2°C to 8°C. Adult travelers represent 90% of recipients in developed markets.

Conjugate Vaccine:Conjugate vaccines dominate with 58% share. Single-dose administration achieves over 80% efficacy in children as young as 6 months. More than 120 million TCV doses were distributed between 2022 and 2024. Routine immunization programs in 45 countries target birth cohorts exceeding 20 million annually. Booster-free schedules reduce compliance drop-offs by 25%. Government tenders account for 85% of conjugate vaccine procurement.

Capsular Polysaccharide Vaccines:Capsular polysaccharide vaccines represent 18% of market share. Single-dose injectable regimens provide protection for approximately 3 years. Protective efficacy averages 55% to 75% in individuals over 2 years. Approximately 500,000 doses are administered annually in travel clinics worldwide. Revaccination is recommended every 3 years for ongoing exposure.

Others:Other vaccine types account for 4% of the Typhoid Fever Vaccines Market Size. Pipeline candidates include protein-based and combination vaccines under phase 2 trials involving over 1,000 participants. Novel adjuvant formulations improved immunogenicity by 15% in early studies. Thermostable candidates aim to maintain potency at 25°C for up to 72 hours.

By Application

Government Institution:Government institutions account for 78% of total vaccine procurement. Over 150 million children are targeted annually through routine and campaign-based immunization. National immunization budgets allocate up to 10% toward typhoid control in high-burden countries. Mass campaigns vaccinate 5 million to 30 million children per country within 6 to 12 months. Cold-chain coverage exceeds 70% in urban centers.

Private Sector:The private sector represents 22% of market share. Travel clinics administer over 500,000 doses annually worldwide. Adult travelers constitute 85% of private-sector demand. Occupational vaccination for laboratory workers and food handlers represents 10% of private immunization. Retail pharmacies account for 40% of private vaccine distribution in developed countries.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

• Asia-Pacific accounts for 68% share with over 140 million doses administered annually.
• Africa holds 18% share with campaign coverage exceeding 40 million children.
• North America contributes 6% share driven by travel vaccination above 250,000 doses annually.
• Europe represents 5% share with strong traveler immunization demand.
• Latin America accounts for 3% share with localized endemic transmission.

North America

North America holds 6% of the Typhoid Fever Vaccines Market Share. The U.S. contributes over 85% of regional volume with 300 to 400 reported cases annually. Travel vaccination accounts for 95% of doses administered. Approximately 250,000 to 300,000 doses are distributed annually through travel clinics and pharmacies. Adult immunization exceeds 90% of regional uptake. Booster compliance remains above 70%. Canada reports fewer than 100 cases annually, with over 80% travel-related. Private-sector procurement represents 88% of regional distribution.

Europe

Europe accounts for 5% of global market share, with approximately 200 to 300 imported typhoid cases reported annually across EU countries. Over 2 million European travelers visit endemic regions each year. Around 300,000 doses are administered annually through private clinics. Adult immunization constitutes 97% of demand. Cold-chain compliance exceeds 90% in healthcare facilities. Booster adherence remains near 65% among repeat travelers.

Asia-Pacific

Asia-Pacific dominates with 68% share. India, Pakistan, Bangladesh, and Indonesia report incidence rates ranging from 100 to 300 cases per 100,000 in high-risk districts. Over 100 million TCV doses are administered annually in the region. National immunization campaigns target 10 million to 30 million children per country. Urban slum populations exceeding 50 million are prioritized. Government procurement accounts for 80% of regional demand.

Middle East & Africa

Middle East & Africa account for 18% of global volume. Sub-Saharan Africa reports incidence rates between 50 and 150 cases per 100,000 in certain districts. Over 40 million children were vaccinated during campaigns between 2022 and 2024. Routine immunization coverage exceeds 60% in urban centers. Cold-chain gaps affect 30% of rural clinics. Government institutions represent 75% of procurement volume.

List of Top Typhoid Fever Vaccines Companies

• Sanofi Pasteur
• Bharat Biotech

Sanofi Pasteur holds approximately 28% global market share in polysaccharide and travel vaccines, distributing products in over 60 countries. Bharat Biotech accounts for nearly 32% share in typhoid conjugate vaccines, supplying more than 70 million doses annually across Asia and Africa.

Investment Analysis and Opportunities

Global investment in typhoid immunization programs increased by 20% between 2021 and 2024. Manufacturing capacity expansions added over 50 million doses annually during 2023 to 2025. Public-private partnerships account for 35% of vaccine introduction initiatives in 20+ countries. Cold-chain infrastructure investments increased storage capacity by 25% in South Asia. Research funding for antimicrobial resistance mitigation represents 15% of infectious disease allocations. Urbanization affecting 55% of the global population enhances vaccine demand in high-density regions. These factors drive Typhoid Fever Vaccines Market Opportunities and strengthen Typhoid Fever Vaccines Market Forecast projections for volume expansion.

New Product Development

New product development in the Typhoid Fever Vaccines Market includes next-generation conjugate vaccines targeting over 85% efficacy across age groups. Phase 3 trials between 2023 and 2025 enrolled more than 5,000 participants in Asia and Africa. Thermostable candidates aim to maintain potency at 30°C for up to 96 hours. Combination vaccines integrating typhoid and paratyphoid antigens are in phase 2 studies with 1,200 participants. Novel adjuvants improved antibody titers by 20% in early trials. Pediatric dose optimization reduced adverse events by 12%. These innovations expand Typhoid Fever Vaccines Market Insights and strengthen Typhoid Fever Vaccines Industry Analysis.

Five Recent Developments (2023–2025)

1. In 2023, a manufacturer expanded TCV production by 30%, adding 20 million doses annually.
2. In 2024, a new country introduced TCV into routine immunization targeting 15 million children.
3. In 2024, phase 3 data involving 3,000 participants reported 83% efficacy over 2 years.
4. In 2025, cold-chain upgrades improved storage capacity by 22% across 10 African countries.
5. In 2025, regulatory approval in 3 additional markets expanded access to 25 million eligible individuals.

Report Coverage of Typhoid Fever Vaccines Market

The Typhoid Fever Vaccines Market Report provides detailed quantitative analysis across 5 regions and more than 60 countries. The Typhoid Fever Vaccines Market Research Report evaluates 7 major manufacturers representing over 90% of global supply. Annual distribution exceeding 250 million doses is assessed in volume terms. Segmentation analysis covers 4 vaccine types and 2 application segments. Epidemiological mapping includes incidence rates ranging from 10 to 300 cases per 100,000 across endemic districts. The Typhoid Fever Vaccines Industry Report examines procurement patterns where government institutions account for 78% of total demand. Clinical pipeline analysis tracks 6 active vaccine candidates in phase 2 and phase 3 trials. The Typhoid Fever Vaccines Market Forecast integrates immunization coverage levels between 60% and 85% in high-risk populations, regulatory frameworks in 45 adopting countries, and cold-chain capacity metrics across 30 national immunization programs, delivering comprehensive Typhoid Fever Vaccines Market Insights for B2B stakeholders.